The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtypes.
Marina Pollán
No relevant relationships to disclose
Bella Pajares
No relevant relationships to disclose
Miguel Martin
Consultant or Advisory Role - Amgen; Roche
John Robert Mackey
Employment or Leadership Position - Sanofi
Honoraria - Sanofi
Ana Lluch
Honoraria - Bristol-Myers Squibb; Roche; Sanofi
Joaquin Gavila
No relevant relationships to disclose
Charles L. Vogel
No relevant relationships to disclose
Manuel Ruiz Borrego
No relevant relationships to disclose
Lourdes Calvo
No relevant relationships to disclose
Tadeusz Pienkowski
No relevant relationships to disclose
Alvaro Rodriguez-Lescure
No relevant relationships to disclose
Miquel Angel Seguí
No relevant relationships to disclose
Olivier Tredan
No relevant relationships to disclose
Antonio Anton
No relevant relationships to disclose
Manuel Ramos Vazquez
No relevant relationships to disclose
M Carmen Camara
No relevant relationships to disclose
Cesar Rodriguez-Martin
No relevant relationships to disclose
Eva Maria Carrasco
No relevant relationships to disclose
Emilio Alba
No relevant relationships to disclose